Cannabidiol Treatment Improves Glucose Metabolism and Memory in Streptozotocin-Induced Alzheimer’s Disease Rat Model: A Proof-of-Concept Study

Daniele de Paula Faria 1,*, Larissa Estessi de Souza 1, Fabio Luís de Souza Duran 2,*, Carlos Alberto Buchpiguel 1, Luiz Roberto Britto 3, José Alexandre de Souza Crippa 4, Geraldo Busatto Filho 2 and Caroline Cristiano Real 1,2,*,†

Abstract: An early and persistent sign of Alzheimer’s disease (AD) is glucose hypometabolism, which can be evaluated by positron emission tomography (PET) with 18F-2-fluoro-2-deoxy-D-glucose ([18F]FDG). Cannabidiol has demonstrated neuroprotective and anti-inflammatory properties but has not been evaluated by PET imaging in an AD model. Intracerebroventricular (icv) injection of streptozotocin (STZ) is a validated model for hypometabolism observed in AD. This proof-of-concept study evaluated the effect of cannabidiol treatment in the brain glucose metabolism of an icv-STZ AD model by PET imaging. Wistar male rats received 3 mg/kg of STZ and [18F]FDG PET images were acquired before and 7 days after STZ injection. Animals were treated with intraperitoneal cannabidiol (20 mg/kg—STZ-cannabidiol) or saline (STZ-saline) for one week. Novel object recognition was performed to evaluate short-term and long-term memory. [18F]FDG uptake in the whole brain was significantly lower in the STZ–saline group. Voxel-based analysis revealed a hypometabolism cluster close to the lateral ventricle, which was smaller in STZ–cannabidiol animals. The brain regions with more evident hypometabolism were the striatum, motor cortex, hippocampus, and thalamus, which was not observed in STZ–cannabidiol animals. In addition, STZ–cannabidiol animals revealed no changes in memory index. Thus, this study suggests that cannabidiol could be an early treatment for the neurodegenerative process observed in AD.

Keywords: cannabidiol; Alzheimer’s disease; streptozotocin; [18F]FDG PET imaging; glucose metabolism

1. Introduction

Alzheimer’s disease (AD) has a multifactorial nature and is the most common neurodegenerative disease, being the main cause of dementia in the world [1]. Animal models have been used to understand the disease mechanisms. Streptozotocin (STZ), a glucosamine–nitrosourea compound [2] derived from soil bacteria and originally developed as an anticancer agent, has been used for diabetes models in animals since 1963. In the mid-1990s, the suggestion was raised that an intracerebroventricular (icv) injection of STZ could be an option to develop an animal model for AD. icv-STZ injection can decrease cerebral glucose uptake and produce multiple other effects that resemble the molecular, pathological, and behavioral features of the sporadic form of AD, including neuroinflammation. The glucose hypometabolism and desensitizing brain insulin receptors, observed in an icv-STZ model, are an early and persistent sign of sporadic AD and can be evaluated by positron emission tomography (PET) with 18F-2-fluoro-2-deoxy-D-glucose ([18F]FDG) [3]. Sporadic AD has...
been recognized as an insulin-resistant brain state (IRBS), and cerebral glucose metabolism has been the focus of preclinical testing of therapeutic interventions [2].

Cannabidiol (CBD) is a cannabinoid of the plant Cannabis sativa and has been suggested as a potential drug intervention for neurodegenerative diseases. The cannabinoid system can modulate cellular and molecular mechanisms, including excitotoxicity, oxidative stress, apoptosis, and inflammation, promoting neuroprotection in animal models. Mice inoculated with human Abeta (1–42) peptide into the right dorsal hippocampus and treated daily with CBD for 7 days showed a significant reduction in Aβ protein expression. In addition, an in vivo, anti-inflammatory effect was demonstrated, with lower iNOS and IL-1 beta protein expression [4]. On the other hand, an AD transgenic model (AβPPSwe/PS1ΔE9 (AβPP × PS1) mice) treated with CBD daily over the period of 8 months did not observe effects on soluble and insoluble Aβ40 or Aβ42 in the cortex and in the hippocampus of the animals but prevented the development of social recognition memory deficits [5]. Treatment for 7 days with cannabinoid type 1 (CB1)-selective receptor agonist arachidonyl-2′-chloroethylamide (ACEA) showed a reversed cognitive impairment and increased anti-apoptotic protein levels in a rat icv-STZ model, and rescue cells from STZ-triggered death and modulated NO release in an in vitro, neuronal model (Neuro-2a neuroblastoma cells) [6]. Despite the evidence of the beneficial effects of the cannabinoid system on neurodegenerative diseases, the use of CBD in icv-STZ has not yet been evaluated, and many doubts remain in the field. Thus, the aim of this proof-of-concept study was to evaluate by [18F]FDG PET the effect of cannabidiol treatment for 7 days on brain glucose metabolism and cognitive function in an icv-STZ rat model.

2. Results
2.1. Blood Glucose Level and Body Weight

The icv-STZ injection did not alter the blood glucose concentration (F(2,21) = 1.278; p = 0.2995; baseline—148 ± 23, STZ—126 ± 20 and STZ + CBD—134 ± 44).

Animals from the STZ group revealed higher body weight loss (18.83% ± 1.54) from the surgery day to the final image when compared to STZ + CBD animals (10.0% ± 1.53, p = 0.0022), Figure 1.

![Figure 1. Comparison of percentage of weight loss (difference from the beginning to the end of the experiment) between non-treated (STZ) and treated animals (STZ + CBD). ** p < 0.01. Acronyms: STZ: streptozotocin, CBD: cannabidiol.](image)

2.2. Novel Object Recognition

The novel object recognition test revealed a worse memory index for STZ animals, both for short-term (53.83 ± 3.12, −20%) and long-term memory (39.17 ± 14.43, −53%), when compared to STZ + CBD animals (SM—67.33 ± 5.13, p = 0.0003; LM—83.67 ± 4.13, p < 0.0001), Figure 2.
Int. J. Mol. Sci. 2022, 23, x FOR PEER REVIEW 3 of 11

Figure 2. Memory index from the novel object recognition test: (A) Short memory index and (B) Long memory index. Acronyms: STZ: streptozotocin, CBD: cannabidiol. *** p < 0.001; **** p < 0.0001.

2.3. [18F]FDG PET Imaging

[18F]FDG PET image data are described in Table 1 and showed, in general, lower uptake in the analyzed brain areas of STZ animals when compared to baseline and STZ + CBD uptake. Figures 3 and 4 show illustrative [18F]FDG PET images and the standardized uptake value (SUV) in the whole brain, respectively.

Figure 3. Illustrative [18F]FDG PET images. MRI template used in the analysis is shown in the top of the figure. [18F]FDG PET images are shown for baseline (first line), streptozotocin animals without treatment (STZ—second line), and STZ animals treated with cannabidiol (STZ + CBD—third line). Left side of the figure shows only the [18F]FDG PET images, and the right side shows the PET images fused to the MRI template. White arrows show the areas with hypometabolism. Acronyms: STZ: streptozotocin, CBD: cannabidiol, [18F]FDG: 18F-2-fluoro-2-deoxy-D-glucose, MRI: magnetic resonance imaging.
Table 1. [18F]FDG uptake (SUV) in different brain regions and statistical comparison between groups.

| Brain Areas                | SUV       | F Value                              | p Value       |
|----------------------------|-----------|--------------------------------------|---------------|
|                            | Baseline  | STZ                                  | STZ + CBD     | STZ vs. STZ + CBD |
| Total Brain                | 1.53 ± 0.12 | 1.33 ± 0.07                          | 1.61 ± 0.08   | F(2,21) = 12.38; p = 0.0003 | p = 0.0026 | p = 0.2291 | p = 0.0003 |
| Striatum                   | 1.72 ± 0.10 | 1.48 ± 0.08                          | 1.78 ± 0.11   | F(2,21) = 15.13; p < 0.0001  | p = 0.0003 | p = 0.5102 | p = 0.0002 |
| Amygdala                   | 1.19 ± 0.08 | 1.18 ± 0.13                          | 1.31 ± 0.10   | F(2,21) = 3.237; p = 0.0595   | p = 0.9592 | p = 0.0789 | p = 0.0901 |
| Frontal cortex             | 1.52 ± 0.20 | 1.30 ± 0.21                          | 1.49 ± 0.16   | F(2,21) = 2.82; p = 0.082     | p = 0.073  | p = 0.929  | p = 0.2269 |
| Hippocampus (anterodorsal) | 1.62 ± 0.13 | 1.45 ± 0.13                          | 1.73 ± 0.10   | F(2,21) = 9.585; p = 0.001    | p = 0.0141 | p = 0.1719 | p = 0.0009 |
| Hippocampus (posterior)    | 1.41 ± 0.08 | 1.23 ± 0.10                          | 1.42 ± 0.10   | F(2,21) = 8.562; p = 0.0019   | p = 0.0029 | p = 0.9606 | p = 0.0054 |
| Hypothalamus               | 1.36 ± 0.10 | 1.31 ± 0.17                          | 1.43 ± 0.18   | F(2,21) = 1.13; p = 0.3427    | p = 0.7261 | p = 0.6092 | p = 0.3125 |
| Motor cortex               | 1.59 ± 0.16 | 1.36 ± 0.13                          | 1.65 ± 0.10   | F(2,21) = 7.203; p = 0.0042   | p = 0.0103 | p = 0.7284 | p = 0.0061 |
| Superior colliculus        | 1.71 ± 0.17 | 1.74 ± 0.22                          | 1.74 ± 0.21   | F(2,21) = 0.0832; p = 0.9205  | p = 0.9394 | p = 0.9424 | p > 0.9999 |
| Thalamus                   | 1.70 ± 0.15 | 1.54 ± 0.15                          | 1.77 ± 0.11   | F(2,21) = 4.34; p = 0.0264    | p = 0.0817 | p = 0.5798 | p = 0.0253 |

Acronyms: STZ: streptozotocin, CBD: cannabidiol, SUV: standardized uptake value.

Figure 4. [18F]FDG uptake (SUV—standardized uptake value) in the whole brain. Comparison of baseline (n = 12), non-treated animals (STZ, n = 6), and cannabidiol-treated animals (STZ + CBD, n = 6). ** p < 0.01; *** p < 0.001. Acronyms: STZ: streptozotocin, CBD: cannabidiol, SUV: standardized uptake value, [18F]FDG: 18F-2-fluoro-2-deoxy-D-glucose.

2.4. Small Animal Molecular Imaging Toolbox

The results of the voxel-based analysis are shown in Figure 5 and Table 2. Uptake of [18F]FDG was significantly lower in STZ rats than in baseline scans and STZ + CBD rats (cluster-level p < 0.05, corrected for family-wise error).
Table 2. Statistical parametric mapping outcome for the clusters.

| Cluster Level          | Voxel Level       | Coordinates | Brain Area                                      |
|------------------------|-------------------|-------------|-------------------------------------------------|
|                        |                   |             | Regions close to lateral ventricle (anterior CPu, cortex, and cc) |
| Categorical design:    |                   |             |                                                 |
| [18F]FDG               |                   |             |                                                 |
| STZ < baseline         | <0.001            | 6298        | 6.88                                            |
|                        |                   |             | 0.8                                             |
|                        |                   |             | 1.6                                             |
|                        |                   |             | −2.6                                            |
| STZ + CBD < baseline   | 0.017             | 1158        | 5.20                                            |
|                        |                   |             | <0.001                                          |
|                        |                   |             | −1.6                                            |
|                        |                   |             | −1.8                                            |
|                        |                   |             | −5.4                                            |
|                        | 0.024             | 1039        | 4.86                                            |
|                        |                   |             | <0.001                                          |
|                        |                   |             | 1.8                                             |
|                        |                   |             | −12.4                                           |
|                        |                   |             | −2.4                                            |
| STZ < STZ + CBD        | 0.008             | 1484        | 4.73                                            |
|                        |                   |             | <0.001                                          |
|                        |                   |             | 0.6                                             |
|                        |                   |             | 2.6                                             |
|                        |                   |             | −4.0                                            |

P_{FWE-corr}: the chance (p) of finding a cluster with this or a greater size, corrected for search volume. \( k_E \) = cluster size. \( T \) = outcome of statistical significance. \( P_{uncorr} \): the chance (p) of finding a voxel with this or a greater T value, uncorrected for search volume. \( x \) = medial–lateral direction—distance relative to bregma (negative values to the left side). \( y \) = anteroposterior distance relative to bregma (negative values to the posterior side). \( z \) = dorsoventral distance relative to bregma. Acronyms: STZ: streptozotocin, CBD: cannabidiol, [18F]FDG: 18F-2-fluoro-2-deoxy-D-glucose.

3. Discussion

This was a proof-of-concept study using [18F]FDG PET imaging as a tool to evaluate the effect of cannabidiol in the icv-STZ rat model of Alzheimer’s disease. Our results showed that [18F]FDG PET imaging was able to detect glucose hypometabolism in the brain of animals with induced icv-STZ and that cannabidiol had a protective effect over the STZ action. Cannabidiol was also able to avoid short- and long-term memory damage in the STZ animal model. As far as we know, this is the first study using [18F]FDG PET imaging to evaluate cannabidiol treatment in the icv-STZ-induced AD animal model.

The STZ animal model is considered an Alzheimer’s disease animal model due to STZ brain effects after intracerebroventricular injection, which is related to the hypothesis that there is an association between type 2 diabetes and AD [2,7]. There is a direct effect of icv-STZ injection on memory, where there is memory disruption just a few hours after the STZ injection [8]. Our findings also showed memory deficit after STZ injection; however,
the short- and long-term memory was preserved by the cannabidiol treatment compared to animals without treatment.

The animals from the STZ group presented significant weight loss compared to the animals treated with cannabidiol. The weight loss was already expected in this animal model and was explained by Poddar et al. [9] as a consequence of a decrease in complex I-III activity. In our treated group the weight loss was approximately 10% compared to baseline, which could be a consequence of the surgery procedure itself.

Xiong and Lim [10], in a recent review, discussed the effects of cannabidiol on AD and presented some possible action mechanisms for this drug: among them, an increase in neurogenesis, decrease in Aβ burden, inflammation and oxidative damage, and improvement in cognitive function which was already shown in AD mice [11]. One of these mechanisms, or all of them, could be responsible for our findings. CBD has already shown anxiolytic, neuroprotective, antidepressant, anti-inflammatory, and immunomodulating effects [12] and also has the potential to be used in combination with other drugs already used in the treatment of AD [13].

[18F]FDG PET imaging is a tool to evaluate glucose metabolism and, in the case of neurodegenerative diseases, such as Alzheimer’s disease, this tool can detect hypometabolism in some brain regions that have a direct correlation with neurodegeneration. Since [18F]FDG is a glucose analogue and its uptake, especially brain uptake, can be changed by the blood glucose level [14], it is important to emphasize that the animals in this study presented no alterations in this parameter, which could be explained by the STZ administration route (intracerebroventricular instead of systemic) and is in agreement with the literature [15].

[18F]FDG PET imaging was able to show a decrease in brain metabolism after icv-STZ injection, as well the protective effect of cannabidiol, which suggests the important role of this imaging technique in the evaluation of treatments for AD. The hypometabolism observed by [18F]FDG PET in our AD model corroborates a previous study [3]. In addition, a recent study [16] used this imaging method in the STZ animal model and, although the authors studied a diabetes model (intraperitoneal STZ injection), and the focus was on sex differences in brain metabolism and not treatment, they also found lower brain uptake in the diabetic rats compared to control animals.

Although STZ changes glucose metabolism systemically, its action is through GLUT2 transporter, which is not present in the blood–brain barrier (BBB) and, therefore, for action in the brain, the STZ needs to be injected intracerebroventricularly [2]. [18F]FDG crosses the BBB by GLUT1 [7] transporters, meaning that there is no influence or competition of the tracer entrance and the STZ.

The voxel-based analysis confirmed the results of VOI analysis where the hypometabolism is more evident in the STZ group compared to baseline and STZ + CBD, starting close to the lateral ventricle where the STZ was injected and including part of cortex and corpus callosum. An unexpected result was the hypometabolism in the region of the third ventricle and cerebellum in the group treated with the cannabidiol compared to baseline. This finding may be related to the migration of STZ injection and/or some action of CBD, for example, cerebellar deactivation [17].

This study has some limitations; the main one being the short period (1 week) of treatment. Previous studies [8,18] show that amyloid load increases from 2 weeks of STZ injection; therefore, this parameter was not measured in our study. There was also the treatment scheme, which could be tested as a chronic treatment (longer), as well as only an acute treatment. Due to the short period of evaluation and the intent to focus on the in vivo technique, we did not perform an in vitro technique, such as immunohistochemistry.

There is still a limited number of studies evaluating the status of brain glucose metabolism in the icv-STZ animal model [19]; therefore, this study is important in providing more data on this topic and also in showing the potential of cannabidiol treatment to improve memory and glucose metabolism in an AD animal model.
4. Materials and Methods

4.1. Animals

All procedures were performed according to the protocol approved by the Institutional Animal Care and Ethics Committee on Animal Use (CEUA) of the University of São Paulo Medical School (FMUSP, Brazil) (protocol number: 984/2018, permission code, 21 February 2018). Outbred, male Charles River Wistar rats (three months old, \( n = 12 \)) were purchased from the central animal facility of the Institute of Biomedical Sciences of the University of São Paulo and group-housed in thermo-regulated (21 ± 2 °C) and humidity-controlled rooms. Food and water were available ad libitum. The rats were acclimatized for at least seven days before starting the experimental protocol. Animals were randomly divided into 2 groups \( (n = 6 \) each): (1) streptozotocin animals (STZ), which were injected bilaterally into the lateral ventricles with STZ; and (2) streptozotocin–cannabidiol animals (STZ + CBD), which were injected bilaterally into the lateral ventricles with STZ and treated with intraperitoneal CBD injection immediately after surgery until the end of the experiment (total of 1 week). Sample size calculation was performed with G*Power 3.1.9.2 software (Universität Düsseldorf, Germany) based on published data for \(^{18}\text{F}\)FDG in other studies.

4.2. Intracerebroventricular Injection of Streptozotocin

The animals were anesthetized with isoflurane mixed with oxygen (5% induction, 2% maintenance, 0.8 L/min) and placed in a stereotaxic apparatus (David Kopf instruments, Tujunga, CA, USA). After craniotomy, two aliquots of 3 \( \mu \)L of STZ (3 mg/kg, icv—freshly dissolved in citrate buffer—0.05 mol/L, pH 4.5—S0130, Sigma, supplier: Merck Life Science ApS, Søborg, Denmark) were injected bilaterally into the lateral ventricles by a needle attached to the Hamilton® syringe (Neuros Syringes—65460-02, Reno, NV, USA). The solution was injected into the lateral ventricles at the following coordinates: \( \text{AP} = 0.8 \text{ mm}; \text{ML} = 1.4 \text{ mm}; \text{and } \text{V} = 3.4 \text{ mm relative to bregma and ventral to the dura mater} \) as previously described [6]. After slow infusion (0.5 \( \mu \)L/min), the syringe needle remained in the infused region for 3 min to avoid reflux of the solution. The incision was sutured. To reduce discomfort, pain medication (ketoprofen—1 mg/kg, s.c., Sanofi-Aventis Farmacêutica, Suzano, São Paulo, Brazil) was given during surgery and at 24 h after surgery. If the rats still showed signs of discomfort after 48 h, an extra dose of analgesic was given.

4.3. Intraperitoneal Administration of Cannabidiol

Half of the animals \( (n = 6) \) received intraperitoneal treatment of cannabidiol 20 mg/kg (Biosynthesis Pharma Group Limited—BSPG, Sandwich, UK) diluted in vehicle solution (2% Tween 80 and 98% saline) immediately after the surgical procedure and on the following 6 days (total of 1 week of treatment).

The study design is represented by the scheme in Figure 6.

![Figure 6. Scheme of study design.](image-url)
4.4. Novel Object Recognition (NOR) Behavioral Test

The NOR was carried out on day 6 after surgery. All objects used for the test had similar textures, colors, and sizes but distinctive shapes. The rats were placed in a rectangular arena (76 × 49 × 57 cm) containing two identical objects (A1 + A2) for the habituation and training phase, as previously described [21], but with some modifications. After 5 min, the rats were removed from the arena and placed in their home cage. After 1 h (short-term memory, SM) and 24 h (long-term memory, LM), the rats were placed in the arena again for 5 min, with one object replaced by a novel object (SM: B + A2, LM: C + A2). The behavioral tests were video recorded for further analysis. Exploration of an object is defined as the time the animal spends with its head oriented towards the object, within two centimeters of the object (sniffing). The discrimination index was calculated by:

\[
\left( \frac{\text{time exploring the new object}}{\text{total time exploring the two objects}} \right) \times 100\%
\]

4.5. PET Imaging

\[^{18}\text{F}]\text{FDG was produced at the Nuclear Medicine Center, FMUSP. \[^{18}\text{F}]\text{FDG PET images were acquired at baseline (before stereotactic surgery) and 1 week after surgery using a small-animal PET scanner (Triumph™—Gamma Medica-Ideas, Northbridge, CA, USA). Rats were anesthetized with isoflurane mixed with oxygen (5% induction, 2% maintenance, 0.8 L/min) and then injected into the penile vein with 37–55 MBq of \[^{18}\text{F}]\text{FDG. Forty-five minutes after the tracer injection, the animals were positioned in the scanner with their heads in the center of the field of view. A static image was acquired for 30 min. The body temperature of the animals was maintained by heating pads, and the breathing rate was monitored, and eye lubricant was applied onto the eyes to prevent dehydration. After the scans, the animals were either allowed to recover in their home cages or euthanized (end of experiment). Emission sinograms were iteratively reconstructed into a single frame of 30 min (OSEM 3D; 20 iterations and 4 subsets) after being normalized and corrected for scatter and radioactivity decay. PET image analysis was performed with PMOD software (PMOD™ Technologies Ltd., Zurich, Switzerland). \[^{18}\text{F}]\text{FDG PET images were registered to MRI template, and volumes of interest (VOI), available on PMOD software, were applied for brain analysis. The brain radioactivity concentration was calculated in each VOI and expressed as standardized uptake value (SUV): }\text{tissue activity concentration (kBq/mL) × body weight (g)}/\text{injected dose (kBq)}\text{ for each region. A tissue density of 1 g/mL was assumed.} \]

4.6. Voxel Based Analysis

Voxel-based analyses [22] were performed in Statistical Parametric Mapping, version 12 (SPM12; https://www.fil.ion.ucl.ac.uk/spm/ accessed on 21 December 2021), accessed/installed on 5 June 2019, using \[^{18}\text{F}]\text{FDG data in combination with the Small Animal Molecular Imaging Toolbox (SAMIT; http://mic-umcg.github.io/samit/ accessed on 21 December 2021) package, accessed/installed on 5 June 2019. All the images were spatially normalized using affine transformations to a tracer-specific rat brain PET template in Paxinos space [23] and smoothed with a 1.2 mm isotropic Gaussian kernel. To ensure that the analysis contained only voxels mapping the rat brain, a threshold of 0.5 of the mean radiotracer uptake in the rat brain was selected. The differences between the global uptake of images were adjusted using the proportional scaling option of SPM12.

For the interpretation of group differences, T map thresholds were set at \(\leq 0.001\), uncorrected for multiple comparisons, and the extent threshold \(\geq 200\) voxels for the cluster size (kE) (voxel size of 0.2 × 0.2 × 0.2 mm). Only clusters with \(p \leq 0.05\), corrected for family-wise error (FWE), were considered significant [24].
4.7. Statistical Analysis

Data are presented as mean and standard deviation (SD). Body weight and novel object recognition data were analyzed using the Student’s t-test. [18F]FDG data for each brain area and blood glucose level were analyzed by one-way ANOVA followed by Tukey’s multiple comparisons test. Differences were considered statistically significant when \( p < 0.05 \). All data were analyzed using GraphPad Prism 6 software (San Diego, CA, USA).

5. Conclusions

Our data suggest that cannabidiol treatment was able to protect the brain from STZ effects, which promoted a dysregulation in the glucose metabolism. The absence of alterations in the glucose metabolism could be important for maintaining cognitive ability, which was altered in the animals without treatment. Therefore, cannabidiol could be an important therapeutic option for Alzheimer’s disease, given that there is early and persistent glucose metabolism dysfunction in this disease, and [18F]FDG PET imaging may be a valuable tool to evaluate its effect.

Author Contributions: Conceptualization, C.C.R., C.A.B., D.d.P.F., G.B.F. and J.A.d.S.C.; methodology, C.C.R., D.d.P.F., L.E.d.S. and F.L.d.S.D.; formal analysis, C.C.R., D.d.P.F. and F.L.d.S.D.; investigation, C.C.R., D.d.P.F. and L.E.d.S.; resources, C.A.B., D.d.P.F. and L.R.B.; data curation, C.C.R., D.d.P.F. and F.L.d.S.D.; writing—original draft preparation, C.C.R. and D.d.P.F.; writing—review and editing, C.C.R., C.A.B., D.d.P.F., G.B.F., J.A.d.S.C. and L.R.B.; supervision, C.C.R. and D.d.P.F.; project administration, C.C.R. and D.d.P.F.; funding acquisition, C.A.B. and D.d.P.F. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Laboratório de Investigação Médica—Hospital das Clínicas (LIM—HC-FMUSP, Brazil—S003 call 11/2017) and São Paulo Research Foundation (FAPESP 2018/15167-1 and 2019/15654-2). C.C.R. had a post-doctoral fellowship from GE healthcare—Sweden (#104.441). The article-processing charge (APC) was funded by FAPESP (2018/15167-1).

Institutional Review Board Statement: The animal study protocol was approved by the Institutional Animal Care and Ethics Committee on Animal Use (CEUA) of the University of São Paulo Medical School (FMUSP, Brazil) (protocol number: 984/2018; approved in 21 February 2018).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data that support the findings of this study are available from the corresponding authors upon reasonable request.

Acknowledgments: Thanks to Mônica Joana Kan Golcman for technical assistance and to Biosynthesis Pharma Group Limited (BSPG) for donating the cannabidiol for this study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Zhang, X.X.; Tian, Y.; Wang, Z.T.; Ma, X.H.; Tan, L.; Yu, J.T. The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention. J. Prev. Alzheimers Dis. 2021, 8, 313–321. [CrossRef] [PubMed]
2. Grieb, P. Intracerebroventricular Streptozotocin Injections as a Model of Alzheimer’s Disease: In Search of a Relevant Mechanism. Mol. Neurobiol. 2016, 53, 1741–1752. [CrossRef] [PubMed]
3. Chen, Y.; Guo, Z.; Mao, Y.F.; Zheng, T.; Zhang, B. Intranasal Insulin Ameliorates Cerebral Hypometabolism, Neuronal Loss, and Astrogliosis in Streptozotocin-Induced Alzheimer’s Rat Model. Neurotox. Res. 2018, 33, 716–724. [CrossRef]
4. Esposito, G.; Scuderi, C.; Savani, C.; Stardo, L.; De Filippis, D.; Cottone, P.; Iuvone, T.; Cuomo, V. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br. J. Pharm. 2007, 151, 1272–1279. [CrossRef]
5. Cheng, D.; Spiro, A.S.; Jenner, A.M.; Garner, B.; Karl, T. Long-Term Cannabidiol Treatment Prevents the Development of Social Recognition Memory Deficits in Alzheimer’s Disease Transgenic Mice. J. Alzheimers Dis. 2014, 42, 1383–1396. [CrossRef]
6. Crunfli, F.; Vrechi, T.A.; Costa, A.P.; Torrao, A.S. Cannabinoid Receptor Type 1 Agonist ACEA Improves Cognitive Deficit on STZ-Induced Neurotoxicity Through Apoptosis Pathway and NO Modulation. Neurotox. Res. 2019, 35, 516–529. [CrossRef]
7. Rebelos, E.; Rinne, J.O.; Nuutila, P.; Ekblad, L.L. Brain Glucose Metabolism in Health, Obesity, and Cognitive Decline—Does Insulin Have Anything to Do with It? A Narrative Review. J. Clin. Med. 2021, 10, 1532. [CrossRef]
8. Santos, T.D.; Mazucanti, C.H.Y.; Xavier, G.F.; Torrao, A.D. Early and late neurodegeneration and memory disruption after intracerebroventricular streptozotocin. *Physiol. Behav.* **2012**, *107*, 401–413. [CrossRef]

9. Poddar, J.; Singh, S.; Kumar, P.; Bali, S.; Gupta, S.; Chakrabarti, S. Inhibition of complex I-III activity of brain mitochondria after intracerebroventricular administration of streptozotocin in rats is possibly related to loss of body weight. *Heliyon* **2020**, *6*, [CrossRef] [PubMed]

10. Xiong, Y.Y.; Lim, C.S. Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease. *Brain Sci.* **2021**, *11*, 1211. [CrossRef]

11. Martin-Moreno, A.M.; Reigada, D.; Ramirez, B.G.; Mechoulam, R.; Innamorato, N.; Cuadrado, A.; de Ceballos, M.L. Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer’s Disease. *Mol. Pharmacol.* **2011**, *79*, 964–973. [CrossRef]

12. Silvestro, S.; Schepici, G.; Bramanti, P.; Mazzon, E. Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease. *Molecules* **2020**, *25*, 5186. [CrossRef]

13. Karl, T.; Cheng, D.; Garner, B.; Arnold, J.C. The therapeutic potential of the endocannabinoid system for Alzheimer’s disease. *Expert Opin. Ther. Targets* **2012**, *16*, 407–420. [CrossRef] [PubMed]

14. Sprinz, C.; Altmaier, S.; Zanon, M.; Wätte, G.; Irion, K.; Marchiori, E.; Hochhegger, B. Effects of blood glucose level on 18F-FDG uptake for PET/CT in normal organs: A systematic review. *PLoS ONE* **2018**, *13*, e0193140. [CrossRef] [PubMed]

15. Song, J.Z.; Cui, S.Y.; Cui, X.Y.; Hu, X.; Ma, Y.N.; Ding, H.; Ye, H.; Zhang, Y.H. Dysfunction of GABAergic neurons in the parafacial zone mediates sleep disturbances in a streptozotocin-induced rat model of sporadic Alzheimer’s disease. *Metab. Brain Dis.* **2018**, *33*, 127–137. [CrossRef] [PubMed]

16. Wu, C.Y.; Lin, Y.H.; Hsieh, H.H.; Lin, J.J.; Peng, S.L. Sex Differences in the Effect of Diabetes on Cerebral Glucose Metabolism. *Biomedicines* **2021**, *9*, 1661. [CrossRef] [PubMed]

17. Sadaka, A.H.; Ozuna, A.G.; Ortiz, R.J.; Kulkarni, P.; Johnson, C.T.; Afshari, A.; Hohman, A.G.; Ferris, C.F. Cannabidiol has a unique effect on global brain activity: A pharmacological, functional MRI study in awake mice. *J. Transl. Med.* **2021**, *19*, 220. [CrossRef] [PubMed]

18. Ravelli, K.G.; Rosario, B.D.; Camarini, R.; Hernandes, M.S.; Britto, L.R. Intracerebroventricular Streptozotocin as a Model of Alzheimer’s Disease: Neurochemical and Behavioral Characterization in Mice. *Neurotox. Res.* **2017**, *31*, 327–333. [CrossRef]

19. Soni, N.D.; Ramesh, A.; Roy, D.; Patel, A.B. Brain energy metabolism in intracerebroventricularly administered streptozotocin mouse model of Alzheimer’s disease: A H-1- C-13 -NMR study. *J. Cereb. Blood Flow Metab.* **2021**, *41*, 2344–2355. [CrossRef]

20. Paxinos, G.; Watson, C. *The Rat Brain in Stereotaxic Coordinates*, 7th ed.; Academic Press: Cambridge, MA, USA, 2013; p. 472.

21. Realf, C.C.; Doorduin, J.; Feltis, P.K.; Garcia, D.V.; Faria, D.D.; Britto, L.R.; de Vries, E.F. Evaluation of exercise-induced modulation of glial activation and dopaminergic damage in a rat model of Parkinson’s disease using C-11 PBR28 and F-18 FDOPA PET. *J. Cereb. Blood Flow Metab.* **2019**, *39*, 989–1004. [CrossRef]

22. Vallez Garcia, D.; Casteels, C.; Schwarz, A.J.; Dierckx, R.; Koole, M.; Doorduin, J. A Standardized Method for the Construction of Tracer-Specific PET and SPECT Rat Brain Templates: Validation and Implementation of a Toolbox. *PLoS ONE* **2015**, *10*, e0122363. [CrossRef] [PubMed]

23. Schwarz, A.J.; Danckaert, A.; Reese, T.; Gozzi, A.; Paxinos, G.; Watson, C.; Merlo-Pich, E.V.; Bifone, A. A stereotaxic MRI template set for the rat brain with tissue class distribution maps and co-registered anatomical atlas: Application to pharmacological MRI. *Neuroimage* **2006**, *32*, 538–550. [CrossRef] [PubMed]

24. Vállez Garcia, D.; de Vries, E.F.; Toyohara, J.; Ishiwata, K.; Hatano, K.; Dierckx, R.A.; Doorduin, J. Evaluation of [(11)C]CB184 for imaging and quantification of TSPO overexpression in a rat model of herpes encephalitis. *Eur. J. Nucl. Med. Mol. Imaging* **2015**, *42*, 1106–1118. [CrossRef] [PubMed]